[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:t-cell-non-hodgkin-lymphoma":3},{"name":4,"total":5,"recruiting":6,"trials":7,"biomarkers":195,"states":200},"T-Cell Non-Hodgkin Lymphoma",30,25,[8,16,22,29,36,42,48,54,60,66,72,78,84,90,96,102,108,114,120,126,132,138,144,150,156,162,169,175,181,188],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT07225985","Pralatrexate With Bendamustine and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma",[12],"Phase 1\u002FPhase 2","RECRUITING","2026-08-26T02:16:34.792807Z","2026-07-05T05:32:16.666005Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":20,"content_modified":21},"NCT05463263","A Phase 1\u002F2 Study of STP938 for Adult Subjects With Relapsed\u002FRefractory B-Cell and T-Cell Lymphomas",[12],"2026-08-26T02:15:26.669629Z","2026-05-05T02:43:29.494912Z",{"nct_id":23,"title":24,"phases":25,"status":13,"updated_at":27,"content_modified":28},"NCT03829540","CD4CAR for CD4+ Leukemia and Lymphoma",[26],"Phase 1","2026-08-26T02:16:16.995720Z","2026-05-05T02:43:29.465176Z",{"nct_id":30,"title":31,"phases":32,"status":13,"updated_at":34,"content_modified":35},"NCT04858256","Pacritinib in Relapsed\u002FRefractory T-cell Lymphoproliferative Neoplasms",[33],"Phase 2","2026-08-26T02:19:12.219640Z","2026-05-05T02:43:29.322813Z",{"nct_id":37,"title":38,"phases":39,"status":13,"updated_at":40,"content_modified":41},"NCT06534060","MB-105 in Patients With CD5 Positive T-cell Lymphoma",[33],"2026-08-26T02:16:20.336282Z","2026-05-05T02:43:29.160324Z",{"nct_id":43,"title":44,"phases":45,"status":13,"updated_at":46,"content_modified":47},"NCT02974647","Study of Ruxolitinib in Relapsed or Refractory T or NK Cell Lymphoma",[33],"2026-08-26T02:18:38.865010Z","2026-05-05T02:43:28.499698Z",{"nct_id":49,"title":50,"phases":51,"status":13,"updated_at":52,"content_modified":53},"NCT05313243","Pembrolizumab and Brentuximab Vedotin in Subjects With Relapsed\u002FRefractory T-cell Lymphoma",[33],"2026-08-26T02:15:34.659160Z","2026-05-05T02:43:27.391034Z",{"nct_id":55,"title":56,"phases":57,"status":13,"updated_at":58,"content_modified":59},"NCT04752826","BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)",[12],"2026-08-26T02:18:42.501841Z","2026-05-05T02:43:28.727191Z",{"nct_id":61,"title":62,"phases":63,"status":13,"updated_at":64,"content_modified":65},"NCT06390319","Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)",[33],"2026-08-26T02:18:39.640967Z","2026-05-05T02:43:28.653429Z",{"nct_id":67,"title":68,"phases":69,"status":13,"updated_at":70,"content_modified":71},"NCT05110742","Phase I\u002FII Study of CD5 CAR Engineered IL15-Transduced Cord Blood-Derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapsed\u002FRefractory Hematological Malignances",[12],"2026-08-26T02:18:40.612983Z","2026-07-30T01:46:14.462113Z",{"nct_id":73,"title":74,"phases":75,"status":13,"updated_at":76,"content_modified":77},"NCT05684965","XTX301 in Patients With Advanced Solid Tumors",[12],"2026-08-26T02:17:30.961790Z","2026-07-05T05:32:16.814936Z",{"nct_id":79,"title":80,"phases":81,"status":13,"updated_at":82,"content_modified":83},"NCT04104776","A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas",[12],"2026-08-26T02:17:15.156099Z","2026-07-05T05:32:16.792523Z",{"nct_id":85,"title":86,"phases":87,"status":13,"updated_at":88,"content_modified":89},"NCT07192471","A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma",[26],"2026-08-26T02:17:59.904383Z","2026-07-05T05:32:16.661363Z",{"nct_id":91,"title":92,"phases":93,"status":13,"updated_at":94,"content_modified":95},"NCT07451054","CD45BE-HSPC + CART-45 Cells",[26],"2026-08-26T02:16:39.977107Z","2026-05-13T02:55:06.706937Z",{"nct_id":97,"title":98,"phases":99,"status":13,"updated_at":100,"content_modified":101},"NCT05079282","Study of ONO-4685 in Patients With Relapsed or Refractory T Cell Lymphoma",[26],"2026-08-26T02:17:12.307088Z","2026-05-05T02:43:29.642831Z",{"nct_id":103,"title":104,"phases":105,"status":13,"updated_at":106,"content_modified":107},"NCT05031897","Two Step Haplo With Radiation Conditioning",[33],"2026-08-26T02:16:32.589113Z","2026-05-05T02:43:29.158573Z",{"nct_id":109,"title":110,"phases":111,"status":13,"updated_at":112,"content_modified":113},"NCT07444632","Phase1 Basket Trial Of CAR.70-Engineered IL15-Transduced With TGFBR2 Knock Out Cord Blood-Derived NK Cells For Relapsed\u002FRefractory Lymphoid Malignancies",[26],"2026-08-26T02:16:36.513735Z","2026-05-05T02:43:28.704804Z",{"nct_id":115,"title":116,"phases":117,"status":13,"updated_at":118,"content_modified":119},"NCT05996185","Study of Mogamulizumab With DA-EPOCH or CHOEP in Patients With Aggressive T-cell Lymphoma",[33],"2026-08-26T02:16:52.995882Z","2026-05-05T02:43:28.341848Z",{"nct_id":121,"title":122,"phases":123,"status":13,"updated_at":124,"content_modified":125},"NCT04288726","Allogeneic CD30.CAR-EBVSTs in Patients With Relapsed or Refractory CD30-Positive Lymphomas",[26],"2026-08-26T02:16:47.762107Z","2026-05-05T02:43:28.120885Z",{"nct_id":127,"title":128,"phases":129,"status":13,"updated_at":130,"content_modified":131},"NCT05805605","Allo HSCT Using RIC and PTCy for Hematological Diseases",[33],"2026-08-26T02:17:29.353236Z","2026-05-05T02:43:28.075410Z",{"nct_id":133,"title":134,"phases":135,"status":13,"updated_at":136,"content_modified":137},"NCT05092451","Phase I\u002FII Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse\u002FRefractory Hematological Malignances",[12],"2026-08-26T02:16:55.892527Z","2026-05-05T02:43:27.847376Z",{"nct_id":139,"title":140,"phases":141,"status":13,"updated_at":142,"content_modified":143},"NCT05475925","A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas",[12],"2026-08-26T02:15:28.524219Z","2026-05-05T02:43:27.068416Z",{"nct_id":145,"title":146,"phases":147,"status":13,"updated_at":148,"content_modified":149},"NCT05010005","A Study of Ruxolitinib and Duvelisib in People With Lymphoma",[26],"2026-08-26T02:16:01.079019Z","2026-05-05T02:43:26.685721Z",{"nct_id":151,"title":152,"phases":153,"status":13,"updated_at":154,"content_modified":155},"NCT03964480","Prospective Observational International Registry of Patients With Newly Diagnosed Peripheral T Cell Lymphoma.",[],"2026-08-26T02:17:00.709807Z","2026-05-13T02:55:06.180384Z",{"nct_id":157,"title":158,"phases":159,"status":13,"updated_at":160,"content_modified":161},"NCT06131801","Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution",[],"2026-08-26T02:15:45.413021Z","2026-05-13T02:55:06.418667Z",{"nct_id":163,"title":164,"phases":165,"status":166,"updated_at":167,"content_modified":168},"NCT07137481","Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Aggressive T Cell Hematological Malignancies",[33],"NOT_YET_RECRUITING","2026-08-26T02:19:17.380174Z","2026-05-05T02:43:28.805067Z",{"nct_id":170,"title":171,"phases":172,"status":166,"updated_at":173,"content_modified":174},"NCT07297160","CD70.CAR for CD70+ Lymphoma, Myeloma and Solid Tumors",[26],"2026-08-26T02:16:46.951087Z","2026-05-05T02:43:27.644388Z",{"nct_id":176,"title":177,"phases":178,"status":166,"updated_at":179,"content_modified":180},"NCT07691450","Belinostat in Combination With Azacitidine or Pralatrexate for the Treatment of Relapse or Refractory T-cell Lymphoma",[26],"2026-08-26T02:16:42.787115Z","2026-07-19T19:36:05.157190Z",{"nct_id":182,"title":183,"phases":184,"status":185,"updated_at":186,"content_modified":187},"NCT03628612","Long-term Follow-up of Patients Treated With Genetically Modified Autologous T Cells",[33],"ENROLLING_BY_INVITATION","2026-08-26T02:19:11.399072Z","2026-06-16T05:54:07.967158Z",{"nct_id":189,"title":190,"phases":191,"status":192,"updated_at":193,"content_modified":194},"NCT03690011","Cell Therapy for High Risk T-Cell Malignancies Using CD7-Specific CAR Expressed On Autologous T Cells",[26],"ACTIVE_NOT_RECRUITING","2026-08-03T03:05:09.265674Z","2026-05-05T02:43:27.128098Z",[196],{"biomarker":197,"count":198,"slug":199},"CD70 Antigen",3,"cd70-antigen",[201,205,209,213,216,219,223,226,230,234,238,241,244,247,250,253],{"state":202,"count":203,"slug":204},"Texas",16,"texas",{"state":206,"count":207,"slug":208},"New York",11,"new-york",{"state":210,"count":211,"slug":212},"California",10,"california",{"state":214,"count":211,"slug":215},"Florida","florida",{"state":217,"count":211,"slug":218},"Pennsylvania","pennsylvania",{"state":220,"count":221,"slug":222},"Massachusetts",8,"massachusetts",{"state":224,"count":221,"slug":225},"Ohio","ohio",{"state":227,"count":228,"slug":229},"New Jersey",6,"new-jersey",{"state":231,"count":232,"slug":233},"Connecticut",5,"connecticut",{"state":235,"count":236,"slug":237},"Missouri",4,"missouri",{"state":239,"count":236,"slug":240},"North Carolina","north-carolina",{"state":242,"count":198,"slug":243},"Colorado","colorado",{"state":245,"count":198,"slug":246},"Georgia","georgia",{"state":248,"count":198,"slug":249},"Michigan","michigan",{"state":251,"count":198,"slug":252},"Oregon","oregon",{"state":254,"count":198,"slug":255},"Washington","washington"]